Frontlight ResearchEarly access
Taking people in United StatesPhase 2
Systems Investigation of Vaccine Responses in Aging and Frailty
Key facts
- Who runs it
- Yale University
- Where
- New Haven, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 96 people, planned
- Started
- 6 Nov 2023
- Expected to end
- May 2029
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Fluzone
- Fluad
- Record updated
- 10 November 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age 21-40 or 65 and older
- Ability to understand and give informed consent (surrogate consent may apply to nursing home subjects who are decisionally impaired, with verbal assent to be obtained from subject)
- Plan to be in the New Haven, CT area for the next 4-6 weeks
Who cannot take part
- Current use of medication, such as antibiotics in past two weeks. To clarify, patients taking antibiotics for the reason of a current acute infection will not be eligible. Those potential participants receiving antibiotics for prophylaxis purposes will be eligible to participate. The intention is not to create a separate group to drawn conclusions, but not to exclude these participants who are not acutely ill
- Previous adverse reaction to influenza vaccine requiring medical attention, such as allergic response (rash, anaphylaxis) or Guillain-Barré syndrome
- Treatment with clinical trial medication
- Evidence of acute infection, identified by self- report of fever or symptoms in past two weeks
- Treatment for cancer in past three months
- History of organ, bone marrow or stem cell transplant, liver cirrhosis, kidney disease requiring dialysis, HIV/AIDS, hepatitis C or active hepatitis B
- Presence of any other condition (e.g., geographical or social), actual or projected, that the investigator feels would restrict or limit the patient's participation for the duration of the study. This provision includes participants who have 50% or more missed appointments in the last three months
- Pregnant/possibly pregnant
- Blood donation of 1 pint or more in past 2 months
This trial is currently available in United States.
- Yale School of MedicineNew Haven, United StatesContact: Irene Matos, RNTaking people
About the trial
What the trial wants to find out
This study will compare the immune response signatures (including immunologic, transcriptomic and metabolomic) of the two influenza vaccines approved for use in adults age 65 and over (Fluad and Fluzone High-Dose).
The 4 groups in the trial
- 21-30 standard dose FluadExisting treatment, for comparison
Participants age 21-30 years will receive the standard dose Fluad
Treatment: Fluad
- 21-30 high dose FluzoneExisting treatment, for comparison
Participants age 21-30 years will receive the high dose Fluzone
Treatment: Fluzone
- ≥65 years standard dose FluadTreatment being tested
Participants age ≥65 years will receive standard dose Fluad
Treatment: Fluad
- ≥65 years high dose FluzoneTreatment being tested
Participants age ≥65 years will receive high dose Fluzone
Treatment: Fluzone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 10 November 2026